Abstract
Biomarkers become more and more important tools in clinical diagnosis of cutaneous malignancies. Furthermore, after vigorous validation, biomarkers may have influence on future prognostic classification systems. Clinical and histopathological parameters such as anatomic site, type of the primary tumor, tumor size, invasion depth, ulceration, vascular invasion, lymph node involvement and others are well established for their prognostic value. Additionally, an increasing variety of molecular markers have now been identified and described, providing a potential powerful platform for a more precise diagnosis and a more accurate prognostic sub-grouping of tumor entities. This might lead to future changes in existing classification systems, and might have consequences for the treatment and outcome of skin cancer patients. Recently published gene expression or proteomic profiling data relate to new marker molecules involved in skin cancer pathogenesis, which may, after validation by suitable studies, represent future prognostic or predictive biomarkers in cutaneous malignancies. The aim of this report is to summarize the currently known serologic and newer immunohistochemical biomarker molecules in the most common cutaneous malignancies malignant melanoma, squamous cell carcinoma, and cutaneous lymphoma, particularly emphasizing their prognostic and predictive significance.
Keywords: Skin cancer, biomarker, prognosis, serum, immunohistochemistry
Current Cancer Therapy Reviews
Title: Prognostic Biomarkers of Cutaneous Malignancies – Serological, Immunohistochemical and Proteomic Approaches
Volume: 4 Issue: 2
Author(s): Dirk Schadendorf, Jochen Utikal, Balwir Matharoo-Ball, Robert C. Rees and Selma Ugurel
Affiliation:
Keywords: Skin cancer, biomarker, prognosis, serum, immunohistochemistry
Abstract: Biomarkers become more and more important tools in clinical diagnosis of cutaneous malignancies. Furthermore, after vigorous validation, biomarkers may have influence on future prognostic classification systems. Clinical and histopathological parameters such as anatomic site, type of the primary tumor, tumor size, invasion depth, ulceration, vascular invasion, lymph node involvement and others are well established for their prognostic value. Additionally, an increasing variety of molecular markers have now been identified and described, providing a potential powerful platform for a more precise diagnosis and a more accurate prognostic sub-grouping of tumor entities. This might lead to future changes in existing classification systems, and might have consequences for the treatment and outcome of skin cancer patients. Recently published gene expression or proteomic profiling data relate to new marker molecules involved in skin cancer pathogenesis, which may, after validation by suitable studies, represent future prognostic or predictive biomarkers in cutaneous malignancies. The aim of this report is to summarize the currently known serologic and newer immunohistochemical biomarker molecules in the most common cutaneous malignancies malignant melanoma, squamous cell carcinoma, and cutaneous lymphoma, particularly emphasizing their prognostic and predictive significance.
Export Options
About this article
Cite this article as:
Schadendorf Dirk, Utikal Jochen, Matharoo-Ball Balwir, Rees C. Robert and Ugurel Selma, Prognostic Biomarkers of Cutaneous Malignancies – Serological, Immunohistochemical and Proteomic Approaches, Current Cancer Therapy Reviews 2008; 4 (2) . https://dx.doi.org/10.2174/157339408784310061
DOI https://dx.doi.org/10.2174/157339408784310061 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Hematopoietic Growth Factors Support in the Elderly Cancer Patients Treated with Antiblastic Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Anti-Cancer Therapies that Utilize Cell Penetrating Peptides
Recent Patents on Anti-Cancer Drug Discovery Radiolabeled RGD Peptides as Integrin alpha(v)beta3–targeted PET Tracers
Current Medicinal Chemistry Management of Inflammatory Bowel Disease Patients with a Cancer History
Current Drug Targets Calcium and Vitamin D Signaling in the Epidermal Response to Wounding
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Enteral Administration of TKIs: Report of a Response to Ceritinib in an ALK-positive NSCLC Patient and Literature Review
Current Drug Targets New Molecules and Strategies in the Field of Anticancer Agents
Current Medicinal Chemistry - Anti-Cancer Agents The c-Met Inhibitors: A New Class of Drugs in the Battle Against Advanced Nonsmall- Cell Lung Cancer
Current Pharmaceutical Design Targeting the Epidermal Growth Factor Receptor Family in Radionuclide Therapy of Tumors – Signal Transduction and DNA Repair
Letters in Drug Design & Discovery Anticancer Potential of Ginger: Mechanistic and Pharmaceutical Aspects
Current Pharmaceutical Design Chronic Inflammation in the Pancreas and Salivary Glands - Lessons from Similarities and Differences in Pathophysiology and Treatment Modalities
Current Pharmaceutical Design CCNE1 Promotes Progression and is Associated with Poor Prognosis in Lung Adenocarcinoma
Current Pharmaceutical Biotechnology “Smart” Nanocarriers: A New Paradigm for Tumor Targeting Drug Delivery Systems
Drug Delivery Letters The Need for Improvement of the Treatment of Advanced and Metastatic Cervical Cancer, the Rationale for Combined Chemo-Immunotherapy
Anti-Cancer Agents in Medicinal Chemistry uPAR as Anti-Cancer Target: Evaluation of Biomarker Potential, Histological Localization, and Antibody-Based Therapy
Current Drug Targets Inventions Designed to Enhance Drug Delivery Across Epithelial and Endothelial Cells Through the Paracellular Pathway
Recent Patents on Drug Delivery & Formulation Multifunctional Materials for Cancer Therapy: From Antitumoral Agents to Innovative Administration
Current Organic Chemistry Chemoradiotherapy of Human Tumors: Novel Approaches from Nanomedicine
Current Pharmaceutical Design An Expanding Appreciation of the Role Chemokine Receptors Play in Cancer Progression
Current Pharmaceutical Design A Suicide Gene Therapy Combining the Improvement of Cyclophosphamide Tumor Cytotoxicity and the Development of an Anti-Tumor Immune Response
Current Gene Therapy